and eplerenone is selective to the aldosterone receptor. Although numerous clinical trials have evaluated the efficacy of each drug, no studies have directly compared spironolactone and eplerenone.

The FDA approved the phase 2 Explore-OSA trial set to assess the highly selective aldosterone synthase inhibitor, ...

Between 30-50% of adults with hypertension have OSA, and this number increases to between 70-80% in adults with resistant hypertension. Additionally, untreated moderate-to-severe OSA increases the ...

An update from Mineralys Therapeutics, Inc. ( (MLYS) ) is now available. Mineralys Therapeutics announced that the U.S. FDA ...

The central repository of the drug and medication centre helps to navigate to different sections. Medindia's platform provides carefully curated details on generics, brand names, side-effects ...

Radnor, Pennsylvania Friday, January 10, 2025, 18:00 Hrs [IST] ...

RADNOR, PA — Mineralys Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved its ...

The aldosterone-renin ratio (ARR) has gained popularity as a screening test for primary hyperaldosteronism, a probably underdiagnosed cause of hypertension. However, studies have yielded varying ...

Use of nonsteroidal anti-inflammatory drugs (NSAIDs), especially over-the-counter formulations, and certain other drug classes are among the risk factors for community-acquired acute kidney injury (CA ...

Lorundrostat, aimed at targeting hypertension through a novel mechanism involving aldosterone regulation ... Gold’s experience with multiple successful drug approvals and navigating the ...